Cargando…
TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes
Toll‐like receptor 2 (TLR2) expressed on antigen presenting cells evokes a series of critical cytokines, which favor the development of tumor‐specific cytotoxic T lymphocytes (CTLs). Therefore, TLR2 represents an attractive cancer immunotherapeutic target. Here, a synthetic library of 14 000 compoun...
Autores principales: | Cen, Xiaohong, Zhu, Gengzhen, Yang, Junjie, Yang, Jianjun, Guo, Jiayin, Jin, Jiabing, Nandakumar, Kutty Selva, Yang, Wei, Yin, Hang, Liu, Shuwen, Cheng, Kui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523386/ https://www.ncbi.nlm.nih.gov/pubmed/31131189 http://dx.doi.org/10.1002/advs.201802042 |
Ejemplares similares
-
Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy
por: Cen, Xiaohong, et al.
Publicado: (2022) -
Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015) -
Potential treatment methods targeting 2019-nCoV infection
por: Zheng, Lu, et al.
Publicado: (2020) -
Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues
por: Nandakumar, Kutty Selva
Publicado: (2018) -
Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases
por: Nandakumar, Kutty Selva
Publicado: (2023)